Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
21.06
+0.31 (1.49%)
At close: Nov 4, 2026, 4:00 PM EST
21.99
+0.93 (4.42%)
After-hours: Nov 4, 2026, 7:58 PM EST
Takeda Pharmaceutical Financials Overview
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 4,693,236 | 4,505,720 | 4,581,551 | 4,263,762 | 4,027,478 | 3,569,006 |
Revenue Growth | 6.25% | -1.65% | 7.45% | 5.87% | 12.85% | 11.61% |
Gross Profit Gross Profit Growth | 3,039,989 | 2,886,506 | 3,010,132 | 2,832,257 | 2,774,315 | 2,441,698 |
Operating Income Operating Income Growth | 777,135 | 607,842 | 562,936 | 502,602 | 619,667 | 600,062 |
Net Income Net Income Growth | 40,795 | -152,390 | 107,928 | 144,067 | 317,017 | 230,059 |
Earnings Per Share EPS Growth | 25.77 | -96.75 | 67.23 | 91.16 | 201.94 | 145.87 |
EPS Growth | 24.94% | - | -26.25% | -54.86% | 38.44% | -38.96% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
GI GI Growth | 1,491,500 | 1,407,460 | 1,357,022 | 1,216,207 | 1,094,541 |
Rare Diseases Rare Diseases Growth | 777,900 | 762,698 | 752,816 | 688,423 | 639,774 |
PDT PDT Growth | 1,101,100 | 1,057,524 | 1,032,662 | 903,699 | 763,359 |
Oncology Oncology Growth | 609,200 | 580,126 | 560,430 | 462,362 | 438,742 |
Vaccines Vaccines Growth | 64,600 | 59,607 | 55,412 | 50,355 | 78,664 |
Neuroscience Neuroscience Growth | 429,100 | 414,343 | 565,816 | 627,014 | 637,711 |
Other Product Other Product Growth | 219,700 | 223,961 | 257,392 | 315,701 | 372,685 |
Revenue (Total) Revenue (Total) Growth | 4,693,200 | 4,505,720 | 4,581,551 | 4,263,762 | 4,027,500 |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 418,533 | 595,054 | 385,113 | 457,800 | 533,530 | 849,695 |
Total Debt Total Debt Growth | 5,357,417 | 5,476,358 | 5,088,590 | 5,463,391 | 4,861,692 | 4,810,649 |
Net Cash (Debt) Net Cash Growth | -4,938,884 | -4,881,304 | -4,703,477 | -5,005,591 | -4,328,162 | -3,960,954 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -3119.25 | -3099.12 | -2929.93 | -3167.41 | -2757.02 | -2511.43 |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 879,670 | 1,041,431 | 1,057,182 | 716,344 | 977,156 | 1,123,105 |
Capital Expenditures CapEx Growth | -186,496 | -176,003 | -200,795 | -175,420 | -140,657 | -123,252 |
Free Cash Flow Free Cash Flow Growth | 693,174 | 865,428 | 856,387 | 540,924 | 836,499 | 999,853 |
Free Cash Flow Growth | -31.89% | 1.06% | 58.32% | -35.34% | -16.34% | 11.13% |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 64.77% | 64.06% | 65.70% | 66.43% | 68.88% | 68.41% |
Operating Margin | 16.56% | 13.49% | 12.29% | 11.79% | 15.39% | 16.81% |
Pretax Margin | -0.05% | -3.16% | 3.82% | 1.24% | 9.31% | 8.48% |
Profit Margin | 0.87% | -3.38% | 2.36% | 3.38% | 7.87% | 6.45% |
FCF Margin | 14.77% | 19.21% | 18.69% | 12.69% | 20.77% | 28.02% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.492 | 200.000 | 196.000 | 188.000 | 180.000 | 180.000 |
Dividend Per Share Growth | -9.35% | 2.04% | 4.25% | 4.44% | 0% | 0% |
Dividend Yield | 2.34% | 3.53% | 4.57% | 4.49% | 4.14% | 5.15% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 258.93 | - | 62.54 | 45.57 | 21.33 | 23.57 |
P/FCF Ratio | 15.18 | 10.34 | 7.88 | 12.14 | 8.08 | 5.42 |
PS Ratio | 2.22 | 1.99 | 1.47 | 1.54 | 1.68 | 1.52 |